Importantly, both proteins are frequently deregulated in many cancers, though there are highly contrasting patterns of overexpression and downregulation reported depending on the tumor type.47–53 There are also reports that ANXA1/2 can function as tumor suppressors and that a decrease in expression can lead to drug resistance. This evidence concerns the gene ANXA1 and cancer.